MedPath

Amphetamine

Generic Name
Amphetamine
Brand Names
Adderall, Adzenys, Dyanavel, Evekeo, Mydayis
Drug Type
Small Molecule
Chemical Formula
C9H13N
CAS Number
300-62-9
Unique Ingredient Identifier
CK833KGX7E
Background

Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers. The first product of Smith, Kline and French was approved by the FDA on 1976.

During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.

Indication

Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.

ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.

On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.

Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Chronic Pain, Depression, Narcolepsy, Obesity
Associated Therapies
-
news.harvard.edu
·

High doses of Adderall may increase psychosis risk

High-dose prescription amphetamine users face over five-fold increased risk of psychosis or mania, with 30 mg+ dextroamphetamine (40 mg Adderall) posing the highest risk, according to McLean Hospital research. The study, published in the American Journal of Psychiatry, highlights the need for dose consideration in prescribing stimulants, with 81% of psychosis or mania cases in high-dose users potentially preventable. No significant risk increase was observed with methylphenidate (Ritalin) use.
additudemag.com
·

Vyvanse Shortage Update: DEA OKs Expanded Production of the ADHD Medication

DEA allows increased production of Vyvanse to address ADHD and BED treatment shortages, with 25% for domestic and 75% for foreign demand. Despite FDA approval for generic Vyvanse production, shortages persist due to active ingredient issues. DEA's quota-setting process faces criticism for causing shortages, prompting consideration of more transparent methods. Vyvanse remains the most popular stimulant among ADDitude survey respondents.
kffhealthnews.org
·

High Adderall Dose Linked To Alarming Risk Of Mental Health Episodes

High Adderall doses linked to fivefold increased risk of first-time psychosis or mania, especially above 40 mg.
drugs.com
·

High Doses of ADHD Meds Could Trigger Psychosis

High doses of ADHD meds like Adderall can increase psychosis risk by over fivefold, with 30mg+ dextroamphetamine (40mg Adderall) posing the highest risk, according to a study in the American Journal of Psychiatry. Dr. Lauren Moran emphasizes dose as a critical factor in psychosis risk and suggests considering alternative ADHD treatments like methylphenidate (Ritalin), which showed no increased risk.
clinicaladvisor.com
·

Amid Shortages, US Allows Expanded Production of ADHD Drug Vyvanse

The DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% to address ongoing ADHD drug shortages, with a 13,478-pound increase including 3434 pounds for domestic and 10,313 pounds for foreign demand.
drugs.com
·

Amid Shortages, U.S. Allows Expanded Production of ADHD Drug Vyvanse

The U.S. DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% due to ongoing ADHD drug shortages, with 13,478 pounds allocated for domestic and foreign demand.
pmc.ncbi.nlm.nih.gov
·

Ryzumvi: Pioneering Advances in Countering Drug-Induced Mydriasis

Mydriasis, excessive pupil dilation, causes vision issues. Ryzumvi, FDA-approved in 2023, treats drug-induced mydriasis effectively, with clinical trials showing safety and efficacy, though it has limitations like contraindications for uveitis and contact lens use.
papers.ssrn.com
·

Compounding Inequities Through Drug Shortages and IP Litigation

The U.S. faces its worst drug shortage in over a decade, with over 300 drugs affected. Compounding pharmacies fill critical gaps by creating unavailable medications, but face IP litigation from drug manufacturers. This article explores the conflict between FDA regulations and IP law, proposing solutions like a patent use exception and name suffixes to ensure patient access to essential drugs.
© Copyright 2025. All Rights Reserved by MedPath